Combined oral contraceptives: Venous thrombosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 11, 2013, Pages

  de Bastos, Marcos ^a   Stegeman, Bernardine H ^b   Rosendaal, Frits R ^c   Van Hylckama Vlieg, Astrid ^c   Helmerhorst, Frans M ^c   Stijnen, Theo ^c   Dekkers, Olaf M ^c  

^a Hospitalar Do Estado de Minas Gerais   (Brazil)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ARTICLE; CLINICAL PROTOCOL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FUNDING; HUMAN; ORAL CONTRACEPTIVE USE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; VEIN THROMBOSIS; WOMEN'S HEALTH;

EID: 85041738269     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010813     Document Type: Article

References (57)

1. Bloemenkamp KW, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Thrombophilias and gynaecology. Best Practice & Research. Clinical Obstetrics & Gynaecology 2003;17(3):509-28.
2. Castoldi E, Rosing J. APC resistance: biological basis and acquired influences. Journal of Thrombosis and Haemostasis 2010;8:445-53.
3. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technology Assessment 2003;7(27):1-173.
4. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. [PUBMED: 9310563]
5. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8.
6. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Medicine 2011;8:e1001026.
7. Gomes MPV, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormonal replacement therapy: a clinical review. Archives of Internal Medicine 2004;164:1965-76.
8. Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton A, Thomas S, et al. Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. Health Technology Assessment 2006;10(15):1-168.
9. Heinemann LAJ, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007;75:328-36.
10. Henzl MR, Edwards JA. Pharmacology of progestins: 17 alpha-hydroxyprogesterone derivatives and progestins of the first and second generation. Progestins and antiprogestins in clinical practice. Marcel Dekker, Inc, New York, USA, 2000:101-32.
11. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
12. Huerta C, Johansson S, Wallander M, Rodriguez LAG. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine 2007;167:935-43.
13. Inman WH, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. British Medical Journal 1970;2:203-9.
14. Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value in Health 2008;11:956-64.
15. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;340:d2151.
16. Jordan W. Pulmonary embolism. Lancet 1961;278:1146-7.
17. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:I22-30.
18. Kemmeren JM, Algra A, Grobbee DF. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:1-9.
19. Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE. Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation. Blood Coagulation & Fibrinolysis 2002;13:373-81.
20. Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thrombosis and Haemostasis 2002;87:199-205.
21. Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, Curvers J, et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 2004;103:927-33.
22. Kluft C, Meijer P, LaGuardia KD, Fisher AC. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. Contraception 2008;77:77-83.
23. Kristman VL, Manno M, Côté P. Methods to account for attrition in longitudinal data: do they work?. European Journal of Epidemiology 2005;20:657-62.
24. Kuhl H. Dienogest. Drugs 1998;56:834-5.
25. Lidegaard O. Thrombotic diseases in young women and the influence of oral contraceptives. American Journal of Obstetrics and Gynecology 1998;179:S62-7.
26. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002;65:187-96.
27. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890.
28. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423.
29. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50-and 30-microgram oestrogen preparations. British Medical Journal 1980;280:1157-61.
30. Næss IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. Journal of Thrombosis and Haemostasis 2007;5:692-9.
31. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011;342:d2139.
32. Qaseem A, Snow V, Barry P, Hornbake ER, Rodnick JE, Tobolic T, et al. The Joint American Academy of Family Physicians/American College of Physicians Panel on deep venous thrombosis/pulmonary embolism. Practice guideline from the American Academy of Family Physicians and the American College of Physicians. Annals of Family Medicine 2007;5:57-62.
33. Rad M, Kluft C, Menard J, Burggraaf J, de Kam ML, Meijer P, et al. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinylestradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. American Journal of Obstetrics and Gynecology 2006;195:72-7.
34. Sanderson S, Tatt ID, Higgins JPT. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. International Journal of Epidemiology 2007;36:666-76.
35. Sitruk-Ware R. New progestagens for contraceptive use. Human Reproduction Updates 2006;12:169-78.
36. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008;61(1-2):151-7.
37. StataCorp LP. STATA Data analysis and statistical software. StataCorp LP, 2011.
38. Stolley PD, Tonascia JA, Tockman MS, Sartwell PS, Rutledge AH, Jacobs MP. Thrombosis with low-estrogen oral contraceptives. American Journal of Epidemiology 1975;102:197-208.
39. Tans G, Van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. British Journal of Haematology 2003;122:465-70.
40. Thijs V, Lemmens R, Fieuws S. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. European Heart Journal 2008;29:1086-92.
41. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. International Journal of Epidemiology 1992;21:48-52.
42. Thorogood M, Villard-Mackintosh L. Combined oral contraceptives: risks and benefits. British Medical Bulletin 1993;49:124-39.
43. Tick LW, Doggen CJ, Rosendaal FR, Faber WR, Bousema MT, Mackay AJ, et al. Predictors of the post-thrombotic syndrome with non-invasive venous examinations in patients 6 weeks after a first episode of deep vein thrombosis. Journal of Thrombosis and Haemostasis 2010;8:2685-92.
44. van Hylckama Vlieg AH, Helmerhorst FM, Vandenbroucke JP, Doggen ICJM, Rosendaal FP. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2321.
45. van Hylckama Vlieg A, Middeldorp S. Hormone therapies and venous thromboembolism: where are we now?. Journal of Thrombosis and Haemostasis 2011;9:257-66.
46. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
47. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KW, Rosendaal FR. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. American Journal of Obstetrics and Gynecology 1997;177:887-91.
48. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. New England Journal of Medicine 2001;344:1527-35.
49. Vandenbroucke JP. Benefits and harms of drug treatments. BMJ 2004;329:2-3.
50. Vandenbroucke JP. What is the best evidence for determining harms of medical treatment?. Canadian Medical Association Journal 2006;174:645-6.
51. Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Medicine 2008;5:339-43.
52. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. British Medical Journal (Clinical Research Edition) 1986;292:526.
53. Wharton C, Blackburn R. Lower dose pills. Population Reports 1988;16:1-31.
54. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:I4-8.
55. Anonymous. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-82.
56. Anonymous. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organization Technical Report Series 1998;877:1-89.
57. Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013;347:f5298. [PUBMED: 24030561]